Key Takeaway: Precision BioSciences has announced the conclusion of its collaboration with Prevail Therapeutics, during which three programs were advanced and proof of concept for the ARCUS technology was demonstrated. The company has exercised its option to regain control of these programs and plans to develop them independently or with new partners.
Price reaction · baseline $12.87 (2024-04-16 close) · hit after-hours · clean, no other DTIL news in the window
day 0 close
-10.6%
day 1
-16.7%
day 3 · peak
-24.8%
Market Sentiment Analysis
POSITIVE FACTORS
Collaboration advanced three programs successfully.
Demonstrated proof of concept for ARCUS technology.
Precision BioSciences regains control of valuable programs.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Productive collaboration advanced three programs and demonstrated proof of concept of ARCUS for gene excision and gene insertion – Precision exercised option to regain control of programs and intends to bring collaboration programs back to develop independently or with new partners – Precision’s
Frequently Asked Questions
What programs did Precision BioSciences advance?
Precision BioSciences advanced three programs during its collaboration with Prevail Therapeutics.
What technology was demonstrated during the collaboration?
The collaboration demonstrated proof of concept for the ARCUS technology for gene excision and insertion.
What is Precision BioSciences' next step after the collaboration?
Precision intends to develop the regained programs independently or with new partners.